<DOC>
	<DOCNO>NCT01092741</DOCNO>
	<brief_summary>Objectives : Primary endpoint : To achieve low level Polymerase Chain Reaction ( PCR ) ratios B-cell antigen receptor ( Bcr-Abl ) /Bcr ( molecular CR ) significant proportion patient 12 month high dos ( 800 mg daily ) Gleevec therapy To increase proportion patient achieve complete cytogenetic response patient Ph-positive chronic phase CML use initial high dose Gleevec therapy . Secondary endpoint : To evaluate duration PCR negativity , cytogenetic response , hematologic control , survival . To analyze difference response rate prognosis within different risk group patient characteristic</brief_summary>
	<brief_title>Late Chronic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>Treatment : Imatinib mesylate new oral medication block protein responsible CML Patients study take 400 mg imatinib twice daily ( morning evening ) . If side effect , dose may lower . If take less 800 mg imatinib , take dose per day divide two dos . Imatinib mesylate take large glass water . After complete 3 12 month therapy , response imatinib mesylate evaluate . Treatment may continue 20 year , long judged best control leukemia . Update June 2010 : Blood test recommend 2 time per year . Your doctor discus often blood test . Bone marrow do doctor think necessary check disease . You must return M. D. Anderson least every year . You may need bone marrow test every visit , blood drawn measure amount disease . If leukemia find 2 year longer blood test call PCR do measure amount disease , doctor may talk stop treatment imatinib . If doctor decide stop therapy , blood test PCR do every 3 6 month . You need return M. D. Anderson blood test do . You may blood take local doctor mail M. D. Anderson . If leukemia find PCR blood test , doctor may recommend restart treatment imatinib . You may decide stay treatment imatinib even PCR blood test show sign leukemia 2 year longer . This investigational study . The FDA authorize use imatinib mesylate patient CML . It dose imatinib mesylate use investigational . A total 50 patient take part study . All enrol M.D . Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Patients age 15 year old diagnosis Phpositive Bcrpositive CML chronic phase CML . They least one category : A . Patients must receive interferon alpha : Failed achieve lose hematologic complete remission ( 3 month therapy interferon ) , Failed achieve lose major cytogenetic remission , Failed achieve lose complete molecular remission ( competitive quantitative PCR &lt; 0.05 % ) , Were intolerant interferon B . Patients late chronic phase ( i.e. , &gt; /= 12 month diagnosis ) receive treatment interferon : Have high risk toxicity IFNA ( e.g. , age &gt; /= 60 year ) , Refuse use IFNA 2 . ECOG performance 02 . 3 . Serum bilirubin less 2mg % , serum creatinine le 2mg % . 1 . NYHA Class 34 heart disease ; Pregnant lactate female 2 . Women pregnancy potential must practice contraception 3 . Patients accelerated phase ( except clonal evolution ) blastic phase exclude . Patients clonal evolution criterion accelerate phase eligible . 4 . Inclusion woman minority : As per NIH policy , woman member minority include protocol refer CML population .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Gleevec</keyword>
	<keyword>STI571</keyword>
	<keyword>CML</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
</DOC>